# Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

> **NCT01415063** · PHASE4 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- RFA
- TACE

## Interventions

- **PROCEDURE:** RFA
- **PROCEDURE:** TACE-RFA

## Key facts

- **NCT ID:** NCT01415063
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2013-03
- **Final completion:** 2014-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2011-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415063, "Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01415063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*